Vestibular Schwannoma
59
13
17
19
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
6.8%
4 terminated out of 59 trials
82.6%
-3.9% vs benchmark
7%
4 trials in Phase 3/4
37%
7 of 19 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 19 completed trials
Clinical Trials (59)
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
Long Term Follow-up Study of AAVAnc80-antiVEGF Gene Therapy
Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma
Evaluating Pre-Treatment Vestibular Physical Therapy Rehab for Patients With Vestibular Schwannomas
Vestibular Schwannoma Organoids
Vestibular Rehabilitation Protocol in Unilateral Vestibular Schwannoma
Role of ChatGPT in Vestibular Schwannoma Management
Study of Aspirin in Patients With Vestibular Schwannoma
Measuring Vestibular Organ Function With Weak Alternating Current Stimulation
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
StableEyes With Active Neurofeedback
Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma
Use of DTT to Define Facial Nerve Position in Vestibular Schwannomas
Mapping of Vestibular Centers Activation Using fMRI in Patients With Vestibular Schwannoma
Steroids for Facial Nerve Function Protection in Post-surgical Vestibular Schwannoma Patients
Early Rehabilitation Using Head Impulse Test for Acute Vestibular Deficit
Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors
Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma
Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular Schwannoma
Vestibular Schwannoma - Radiosurgery or Expectation: V-REX.